Executive summary The 2024 update of the Lancet Commission on dementia provides new
hopeful evidence about dementia prevention, intervention, and care. As people live longer …

Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical
features, with α-synuclein pathology as the gold standard to establish the definitive …

Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical
presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; …

Synucleinopathies are clinically and pathologically heterogeneous disorders characterized
by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies …

In Parkinson disease (PD), pathological processes and neurodegeneration begin long
before the cardinal motor symptoms develop and enable clinical diagnosis. In this prodromal …

Parkinson's disease is characterized by the presence of abnormal, intraneuronal α-
synuclein aggregates, which may propagate from cell-to-cell in a prion-like manner …

The dual-hit hypothesis of Parkinson's disease (PD) originally postulated that a neurotropic
pathogen leads to formation of α-synuclein pathology in the olfactory bulb (OB) and dorsal …

Parkinson's disease is increasingly prevalent. It progresses from the pre-motor stage
(characterised by non-motor symptoms like REM sleep behaviour disorder), to the disabling …

Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly
regarded as being in the early stages of a progressive neurodegenerative disease involving …

Parkinson's disease prevalence is rapidly increasing in an aging global population. With this
increase comes exponentially rising social and economic costs, emphasizing the immediate …